Qkine launches cell therapy grade recombinant proteins to support next-generation therapies
Qkine introduce new animal origin-free cell therapy grade recombinant protein range
Qkine, Ltd., a specialist bioactive protein manufacturer with its core technology developed at the University of Cambridge, today announced the launch of its Cell Therapy Grade proteins, engineered to support the stringent requirements of cell therapy research, process development, and GMP manufacturing.
Cell therapy is rapidly transforming modern medicine, offering new hope for patients with cancer, autoimmune conditions, and genetic disorders. However, the development and manufacturing of these therapies demand reagents of uncompromising quality, consistency, and safety. Qkine’s new Cell Therapy Grade proteins address this critical need by delivering:
- Defined manufacturing standards – Produced under controlled conditions with full traceability and regulatory support documentation
- Enhanced quality attributes – High purity, animal origin-free, low endotoxin levels, and reduced host cell protein/DNA contamination
- Scalability for clinical workflows – Consistent performance from research-grade to therapy-grade materials, enabling seamless transition to GMP production
- Regulatory readiness – Comprehensive Certificates of Analysis (CoA), Safety Data Sheets (SDS), and technical dossiers to support IND and clinical submissions
“As the cell and gene therapy field matures, the importance of starting materials that are designed for regulatory expectations cannot be overstated,” said Rob Nixon, Commercial Direct at Qkine. “Our Cell Therapy Grade Proteins provide developers with high-performance reagents backed by the documentation and quality systems required to advance from discovery through clinical and commercial manufacturing.”
The portfolio supports a wide range of applications, including CAR-T and TCR therapies, NK cell expansion, iPSC differentiation, and ex vivo gene editing workflows.
The launch represents Qkine’s commitment to empowering the cell therapy ecosystem with high-quality, regulatory-ready tools that streamline process development, accelerate timelines, and reduce risk in bringing life-changing therapies to patients.
The Cell Therapy Grade Proteins are available globally, with customization options for scale, formulation, and regulatory documentation packages.
